Chemotherapy combined with or without targeted therapy is the fundamental treatment for
metastatic colorectal cancer (mCRC). Due to the adverse effects of chemotherapeutic drugs …

Major histocompatibility class I (MHC I) molecules bind peptides derived from a cell's
expressed genes and then transport and display this antigenic information on the cell …

DNA mismatch repair-deficient (MMR-d) cancers present an abundance of neoantigens that
is thought to explain their exceptional responsiveness to immune checkpoint blockade …

Colorectal cancer (CRC) is highly heterogeneous at the genetic and molecular level, which
has major repercussions on the efficacy of immunotherapy. A small subset of CRCs exhibit …

Metastatic colorectal cancer (CRC) with a mismatch repair-deficiency (MMR-
D)/microsatellite instability-high (MSI-H) phenotype carries unique characteristics such as …

Purpose: To determine the prevalence and prognostic value of mismatch repair (MMR)
status and its relation to BRAF mutation (BRAF MT) status in metastatic colorectal cancer …

Although it was thought that apoptotic cells, when rapidly phagocytosed, underwent a silent
death that did not trigger an immune response, in recent years a new concept of …

Conditional gene expression has greatly facilitated the examination of the functions of
particular gene products. Using the Cre/lox P switching expression system, we plan to …

The immunotherapeutic treatment of various cancers with an increasing number of immune
checkpoint inhibitors (ICIs) has profoundly improved the clinical management of advanced …

Cancer immunotherapy has experienced remarkable advances in recent years. Striking
clinical responses have been achieved for several types of solid cancers (eg melanoma …